Open Access
HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer
Publication type: Journal Article
Publication date: 2022-07-01
scimago Q1
wos Q1
SJR: 1.315
CiteScore: 10.9
Impact factor: 5.1
ISSN: 00243205, 18790631
PubMed ID:
35533759
General Biochemistry, Genetics and Molecular Biology
General Medicine
General Pharmacology, Toxicology and Pharmaceutics
Abstract
In tumor cells, the endoplasmic reticulum (ER) plays an essential role in maintaining cellular proteostasis by stimulating unfolded protein response (UPR) underlying stress conditions. ER-associated degradation (ERAD) is a critical pathway of the UPR to protect cells from ER stress-induced apoptosis and the elimination of unfolded or misfolded proteins by the ubiquitin-proteasome system (UPS). 3-Hydroxy-3-methylglutaryl reductase degradation (HRD1) as an E3 ubiquitin ligase plays an essential role in the ubiquitination and dislocation of misfolded protein in ERAD. In addition, HRD1 can target other normal folded proteins. In various types of cancer, the expression of HRD1 is dysregulated, and it targets different molecules to develop cancer hallmarks or suppress the progression of the disease. Recent investigations have defined the role of HRD1 in drug resistance in types of cancer. This review focuses on the molecular mechanisms of HRD1 and its roles in cancer pathogenesis and discusses the worthiness of targeting HRD1 as a novel therapeutic strategy in cancer.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
|
|
|
Cell Death and Disease
3 publications, 17.65%
|
|
|
Cell Cycle
1 publication, 5.88%
|
|
|
Oxidative Medicine and Cellular Longevity
1 publication, 5.88%
|
|
|
Frontiers in Immunology
1 publication, 5.88%
|
|
|
Frontiers in Oncology
1 publication, 5.88%
|
|
|
International Journal of Molecular Sciences
1 publication, 5.88%
|
|
|
Cancer Cell International
1 publication, 5.88%
|
|
|
Cell Biology International
1 publication, 5.88%
|
|
|
Cardiovascular Research
1 publication, 5.88%
|
|
|
International Immunopharmacology
1 publication, 5.88%
|
|
|
BioFactors
1 publication, 5.88%
|
|
|
Immunologic Research
1 publication, 5.88%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 5.88%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
|
|
|
Springer Nature
5 publications, 29.41%
|
|
|
Frontiers Media S.A.
2 publications, 11.76%
|
|
|
Wiley
2 publications, 11.76%
|
|
|
Elsevier
2 publications, 11.76%
|
|
|
Taylor & Francis
1 publication, 5.88%
|
|
|
Hindawi Limited
1 publication, 5.88%
|
|
|
MDPI
1 publication, 5.88%
|
|
|
Oxford University Press
1 publication, 5.88%
|
|
|
Cold Spring Harbor Laboratory
1 publication, 5.88%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
17
Total citations:
17
Citations from 2025:
7
(41.17%)
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Karamali N. et al. HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer // Life Sciences. 2022. Vol. 301. p. 120620.
GOST all authors (up to 50)
Copy
Karamali N., Ebrahimnezhad S., Khaleghi Moghadam R., Daneshfar N., Rezaiemanesh A. HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer // Life Sciences. 2022. Vol. 301. p. 120620.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.lfs.2022.120620
UR - https://doi.org/10.1016/j.lfs.2022.120620
TI - HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer
T2 - Life Sciences
AU - Karamali, Negin
AU - Ebrahimnezhad, Samaneh
AU - Khaleghi Moghadam, Reihaneh
AU - Daneshfar, Niloofar
AU - Rezaiemanesh, Alireza
PY - 2022
DA - 2022/07/01
PB - Elsevier
SP - 120620
VL - 301
PMID - 35533759
SN - 0024-3205
SN - 1879-0631
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2022_Karamali,
author = {Negin Karamali and Samaneh Ebrahimnezhad and Reihaneh Khaleghi Moghadam and Niloofar Daneshfar and Alireza Rezaiemanesh},
title = {HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer},
journal = {Life Sciences},
year = {2022},
volume = {301},
publisher = {Elsevier},
month = {jul},
url = {https://doi.org/10.1016/j.lfs.2022.120620},
pages = {120620},
doi = {10.1016/j.lfs.2022.120620}
}